Syndax Pharmaceuticals Záväzky 2024

Čo robí Syndax Pharmaceuticals?

Syndax Pharmaceuticals Inc. is a biotechnology company based in Waltham, Massachusetts that focuses on the development of novel therapeutics for cancer and immune disorders. The company was founded in 2005 by Arlene Morris and has been listed on NASDAQ since 2014. Business model and product pipeline: Syndax develops small molecules that are capable of modulating epigenetic changes in cells. This approach is based on the understanding that cancer cells often have genetic alterations that result in changes in gene expression. By modulating such epigenetic changes, cancer cells can function normally again, which can help stop or inhibit the growth of cancer cells. The company's product pipeline includes several drugs that are being developed in various stages of clinical research. One of the most advanced programs is E2112, an orally administered drug targeting breast cancer. The drug is currently in Phase III studies that are investigating the efficacy and safety of the drug in combination with other standard therapies. Another promising program is SNDX-6352, an anti-CSF-1 receptor antibody being developed for the treatment of various types of cancer, including certain solid tumors and hematologic malignancies. The drug has been successfully tested in Phase Ib studies, and the company is currently planning to evaluate it in further clinical trials. In addition to cancer research, Syndax is also working on the development of therapeutics for various inflammatory and immunologic diseases. The company is working on a program for the treatment of idiopathic pulmonary fibrosis and also a program for the treatment of thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. In addition to internally developed drugs, the company is collaborating with other biotechnology and pharmaceutical companies to explore innovative treatment options for other diseases. The company has entered into a partnership with Japanese company Kyowa Hakko Kirin Co. Ltd. to develop and market the SNDX-6352 program. Current developments: Syndax has recently experienced strong growth and is investing significantly in research and development to expand its pipeline and expand its drugs. The company recently completed a financing round that raised $80 million to advance its development projects. A key milestone for the company was the appointment of Briggs W. Morrison as CEO in 2020. Morrison, an experienced pharmaceutical manager, was previously the Chief Executive Officer and President of Syndax until 2016. He is now returning to the company and leading efforts to develop innovative therapeutics. Morrison has previously worked at Pfizer and AstraZeneca, bringing valuable experience in the development and marketing of new drugs. Summary: Syndax Pharmaceuticals Inc. is a biotechnology company that focuses on the development of drugs for cancer and inflammatory diseases. The company has a promising product pipeline that includes several therapeutics in various stages of development, including E2112 and SNDX-6352. Syndax recently completed a strong financing round and plans to continue its research and development efforts to discover and develop new innovative therapeutics. Syndax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.